Related Experiment Video
Updated: Jul 13, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
Trastuzumab in the adjuvant treatment of breast cancer
D Svetlovska1, J Mardiak, V Kristova
1National Cancer Institute, Bratislava, Slovakia. daniela.svetlovska@nou.sk
Abstract:
Four large randomized trials to assess efficacy and toxicity of trastuzumab in adjuvant systemic therapy of breast cancer have been initiated. Results clearly demonstrate, that adjuvant treatment of trastuzumab significantly improves outcomes for women with HER2 positive breast cancer. The clinically most significant adverse events of trastuzumab are serious-infusion related reactions and cardiotoxicity. Benefit for patient should be considered according to advantage versus risk (Tab. 1, Fig. 2, Ref. 17) Full Text (Free, PDF) www.bmj.sk.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Tumor Immunotherapy